News

Date Title
July 24, 2017
NEW YORK (GenomeWeb) – As liquid biopsy genetic tests have rocketed into clinical practice over the last handful of years, clinical researchers, test developers, and others have begun to pay increasing attention to a relative lack of tools to ensure assays are validated and performed according to common, or at least equivalent standards
July 18, 2017
The lack of adequate circulating tumour DNA reference materials for developing and measuring safe, accurate, and reproducible assays continues to be a challenge for clinical labs.
June 28, 2017
Clinical labs are adopting next-generation sequencing technology at ever increasing rates. As sequencing costs decrease and the clinical utility of many applications increase, labs are rushing to implement clinical sequencing assays in part to keep critical patient testing volumes for cancer and inherited disease testing from leaving their networks.
April 1, 2017
SeraCare Life Sciences features in Genetic Engineering & Biotechnology News: Think of cancer as criminal activity, and you'll understand the need to properly secure evidence from liquid biopsies.
July 14, 2016
NEW YORK (GenomeWeb) – SeraCare Life Sciences has announced a collaboration with the US National Institute of Standards and Technology (NIST) to develop circulating tumor DNA (ctDNA) reference standard materials for diagnostics.
June 21, 2016
SeraCare Life Sciences, Milford, Mass, has launched the AccuPlex Zika reference material to fast-track the development and validation of polymerase chain reaction (PCR)-based Zika virus assays
May 13, 2016
SeraCare Life Sciences has launched AccuPlex Zika Reference Material, which is designed to fast-track the development and validation of PCR-based Zika virus assays.
April 21, 2016
SeraCare and Toma Bio have developed a solid tumor gene analysis kit. — GenomeWeb